QR kȏd

Increased integration and synergy in EEG- and fNIRS-based data in migraine patients after a three-month treatment with galcanezumab: relations with long-term clinical outcome

Abstract Galcanezumab is a well-tolerated monoclonal antibody developed for migraine prophylaxis. Although its action mechanisms are not fully understood, they may involve changes in cortical connectivity. This study explores galcanezumab-induced central changes by investigating metabolic-electrical...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Glavni autori: Marianna La Rocca, Antonio Lacalamita, Livio Clemente, Giulia Paparella, Elena Ammendola, Nicola Amoroso, Emmanuella Ladisa, Alfonso Monaco, Sebastiano Stramaglia, Roberto Bellotti, Marina de Tommaso
Format: Artigo
Jezik:Inglês
Izdano: Nature Portfolio 2025-12-01
Serija:Scientific Reports
Teme:
Online pristup:https://doi.org/10.1038/s41598-025-30274-0
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!